# Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of TNBC

Source: https://onco.cc/trials/nct06165900/  
OnCo record `nct06165900` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of adebrelimab and carboplatin in triple-negative breast cancer, run by Shengjing Hospital, now recruiting.

## Summary

Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of TNBC is a phase 2, randomised interventional study registered as NCT06165900 by Shengjing Hospital, with a registry enrolment figure of 136 participants, started 2023-09-26 and due to reach its primary completion in 2025-12-15. Interventions recorded: adebrelimab plus stereotactic radiotherapy followed by adebrelimab plus chemotherapy (nab-paclitaxel + carboplatin); adebrelimab plus chemotherapy (nab-paclitaxel + carboplatin). Conditions listed: Stereotactic Radiotherapy; Immunotherapy; Breast Cancer. Triple-negative eligibility wording from the registry: "* Histopathologically confirmed early or locally advanced triple-negative invasive breast cancer according to the latest ASCO/CAP guidelines, meeting the following conditions: (1) pathological type is triple-negative, specifically: ER negative: IHC \< 1%, PR negative: IHC \< 1%, HER2 negative: IHC 0". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT06165900
- Phase: 2
- Setting: A Multicenter, Randomized Trial of Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) Versus Adebrelimab Combined With TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of Triple-negative Breast Cancer
- Sponsor: Shengjing Hospital
- Enrolled: 136

## Sources

- ClinicalTrials.gov NCT06165900: https://clinicaltrials.gov/study/NCT06165900

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/), [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Adebrelimab](https://onco.cc/drugs/adebrelimab/), [Carboplatin](https://onco.cc/drugs/carboplatin/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06165900.json